JAG1 and lung carcinoma: γ-secretase inhibitors can successfully block Notch2–Jagged1 interaction to prevent VM formation, thus providing new avenues for using this strategy as adjuvants to improve the efficiency or resistance of antiangiogenic therapies for lung cancer.